Crizanlizumab inhibits white blood cell-endothelial and platelet-endothelial interactions on blood vessel wall.
Sep
18
2021
Sep
18
2021
Crizanlizumab inhibits white blood cell-endothelial and platelet-endothelial interactions on blood vessel wall.